Glenmark Life Sciences Ltd share price logo

Glenmark Life Sciences Ltd (GLS)


Get free price alerts. Set up your Free investment account to get Live Prices.
Q3 '23 Results
News and Events

Insights on Glenmark Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.


    MF Holding Up


    Mutual Funds have increased holdings from 0.59% to 0.93% in Mar 2024 quarter


    FII Holding Up


    Foreign Institutions have increased holdings from 4.57% to 5.01% in Mar 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged


    Promoters holdings remained unchanged at 82.85% of holdings in Mar 2024 quarter

  • imgNO EFFECT

    Against Peers


    In the last 1 year, Zydus Lifesciences Ltd has given 96.3% return, outperforming this stock by 50.4%


    Retail Holding Down


    Retail Investor have decreased holdings from 11.84% to 10.73% in Mar 2024 quarter


    Price Dip


    In the last 7 days, GLS stock has moved down by -3.2%


  • Day's Low

    Day's High

  • 52 Week's Low

    52 Week's High

1 Month Return-0.3 %
3 Month Return+ 10.09 %
1 Year Return+ 45.85 %
Previous Close₹839.65
Upper Circuit-
Lower Circuit-
Market Cap₹10,287.99Cr

Analyst Rating

based on 5 analysts


Based on 5 analysts offering long term price targets for Glenmark Life Sciences Ltd. An average target of ₹932.6

Source: S&P Global Market Intelligence

Company Information

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Share Price: ₹829.75 per share as on 21 Jun, 2024 04:01 PM
Market Capitalisation: ₹10,287.99Cr as of today
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Life Sciences Ltd
E-voting on sharesClick here to vote

Key events for Glenmark Life Sciences Ltd

  • Glenmark Life Sciences Reports 57% Return in a Year - 19 May, 2024

    Glenmark Life Sciences has reported a net profit margin of 28%, with revenue from operations decreasing by 13.6% YoY. Despite this, the company delivered a return of 57% over the past year.

  • Glenmark Life Sciences Receives Acquisition Approval; ICICI Direct Initiates Coverage with Buy Rating - 02 May, 2024

    Glenmark Life Sciences' parent company, Glenmark Pharmaceuticals, owns 82.84%. Nirma has received approval to acquire the company for Rs. 5,651.50 crore. ICICI Direct initiated coverage with a Buy rating and target price of Rs. 1,040.

  • Glenmark Life Sciences Q4 Results Show Decrease in Revenue and Profit - 28 Apr, 2024

    Glenmark Life Sciences' Q4 results reveal a decline in revenue and profit YoY and QoQ. The EPS is ₹7.97 for Q4, down by 33.32% YoY. The company has delivered -6.19% return in the last 1 week.

  • Glenmark Life Sciences Q4 Net Sales Down 13.64% YoY - 26 Apr, 2024

    Glenmark Life Sciences reported a decrease in net sales, net profit, EBITDA and EPS for the quarter ending March 2024 compared to the same period last year. The stock has given positive returns of 21.64% over the last 6 months and 61.00% over the last 12 months.

  • Glenmark Life Sciences Reports Decline in Q4 FY24 Earnings - 25 Apr, 2024

    Glenmark Life Sciences reported a significant drop in net profit and revenue from operations for the fourth quarter of fiscal year 2023-24. Despite this, the company remains optimistic about future growth due to strong order book and demand visibility.

Mutual Fund Holdings

Funds Holdings
Union Small Cap Fund Direct GrowthUnion Small Cap Fund Direct Growth1.39%
Union Flexi Cap Fund Direct Growth OptionUnion Flexi Cap Fund Direct Growth Option0.91%
Old Bridge Focused Equity Fund Direct Growth3.54%
Union Multicap Fund Direct GrowthUnion Multicap Fund Direct Growth1.28%
Union Innovation & Opportunities Fund Direct GrowthUnion Innovation & Opportunities Fund Direct Growth1.58%

Shareholding Pattern

InvestorsHoldings %Prev. 1 periods3M change
Promoter Holdings
Foreign Institutions
Mutual Funds
Retail Investors

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glenmark Life Sciences Ltd shares.

Glenmark Life Sciences Ltd (GLS) share price today is ₹829.75

Glenmark Life Sciences Ltd is listed on NSE

Glenmark Life Sciences Ltd is listed on BSE

  • Today’s highest price of Glenmark Life Sciences Ltd is ₹847.
  • Today’s lowest price of Glenmark Life Sciences Ltd is ₹825.8.

Today’s traded volume of Glenmark Life Sciences Ltd(GLS) is 43.07K.

Today’s market capitalisation of Glenmark Life Sciences Ltd(GLS) is ₹10287.99Cr.

Glenmark Life Sciences Ltd(GLSPrice
52 Week High
52 Week Low

Glenmark Life Sciences Ltd(GLS) share price is ₹829.75. It is down -8.42% from its 52 Week High price of ₹906

Glenmark Life Sciences Ltd(GLS) share price is ₹829.75. It is up 49.28% from its 52 Week Low price of ₹555.85

Glenmark Life Sciences Ltd(GLSReturns
1 Day Returns
1 Month Returns
3 Month Returns
1 Year Returns